Company intelligence / Profile preview

Rxilient Health

Ownership: Private
Development stage: Commercial

Overview

Rxilient Health focuses on developing, registering, supplying, and commercializing pharmaceutical products for emerging markets, particularly in Southeast Asia. It has a portfolio of over ten differentiated products and is working on registering innovative pipeline products.

Therapeutic areas: OncologyImmunologyDermatologyOphthalmologyNeurology
Modalities: Small moleculesmonoclonal antibodies (e.g., toripalimab)
Industry: Biotech

Drug pipeline

4 assets

Rxolve Ultra

Unknown

3 more assets in the full pipeline.

Request access →

Partnerships

Junshi Biosciences for toripalimab

Beyond the preview

Go deeper on Rxilient Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rxilient Health.

Explore the full profile